Vignesh Packiam

Associate Professor of Urology

Rutgers Cancer Institute of New Jersey

United States

Research Interests

Explore related searches

Professors in United States

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Vignesh Packiam is an Associate Professor of Urology at Rutgers Cancer Institute of New Jersey. His research focuses on innovative treatment strategies for non-muscle invasive bladder cancer (NMIBC) and the optimization of surgical procedures in urology. Recent articles authored by Dr. Packiam discuss the efficacy of various chemotherapy regimens and the potential overuse of post-procedural antimicrobials in endourology. He contributes to the academic community by addressing contemporary treatment approaches and the long-term outcomes for patients with bladder cancer.

Articles (10)

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2022

Collaborators (3)

Ian McElree

Vanderbilt University Medical Center

UNITED STATES

View details

Michael O'Donnell

Harvard University

UNITED STATES

View details

Yousef Zakharia

The University of Iowa

UNITED STATES

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Vignesh Packiam

Research Interests

Explore related searches

Contact this professor

About

Articles (10)

Editorial Comment

The role of blue light cystoscopy and additional operative evaluations during first surveillance after induction therapy for high-risk NMIBC

A pilot intervention trial to reduce the use of post-procedural antimicrobials after common endourologic surgeries

Sequential Endoluminal Gemcitabine and Cabazitaxel with Intravenous Pembrolizumab as a Bladder-Preserving Strategy for Docetaxel-Unresponsive Non-Muscle Invasive Urothelial Carcinoma Following Transurethral Resection of Bladder Tumor

Sequential Endoluminal Doxorubicin and Gemcitabine Alternating Weekly with Sequential Mitomycin and Docetaxel for Recurrent Non-Muscle Invasive Urothelial Carcinoma

Letter: Efficacy of Intravesical Nadofaragene Firadenovec for Patients With Bacillus Calmette-Guérin–Unresponsive Nonmuscle-Invasive Bladder Cancer: 5-Year Follow-Up From a Phase 3 Trial

Contemporary Treatment of NMIBC—Is It Time to Move on from BCG?

Sequential intravesical gemcitabine and docetaxel for treatment-naïve and previously treated intermediate-risk nonmuscle invasive bladder cancer

Long-term follow-up of sequential intravesical gemcitabine and docetaxel salvage therapy for non-muscle invasive bladder cancer

Reply by Authors.

Collaborators (3)

Ian McElree

Michael O'Donnell

Yousef Zakharia

Make your next move.